<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428842</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2013-02 BIO-RAIDs</org_study_id>
    <nct_id>NCT02428842</nct_id>
  </id_info>
  <brief_title>Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)</brief_title>
  <acronym>BIO-RAIDs</acronym>
  <official_title>Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Multicentric European trial for Cervical cancer, not previously treated, with
      tumour biopsies, and blood collection for molecular analysis at predetermined time points.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between tumor biological profile and treatment response.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Dominant mutations and activation pathways in cervical cancers is assessed from tumor biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival evaluation</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Number of patient with no local/metastasis relapse 18 months after end of primary treatment course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard treatment description (Description of primary treatment course regarding : - Initial FIGO ( International Federation of Gynecology and Obstetrics ) staging at baseline - Geographic location(country)</measure>
    <time_frame>up to six months</time_frame>
    <description>Description of primary treatment course regarding :
Initial FIGO ( International Federation of Gynecology and Obstetrics
) staging at baseline
Geographic location(country)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard treatment's side effects description (assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale - National Cancer Institute Common Toxicity Criteria for Adverse Effects)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Description of standard treatment's side effects will be assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular tumor alterations description (Description of molecular tumor alterations regarding geographic location (country)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Description of molecular tumor alterations regarding geographic location (country)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">419</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient will undergo standard care with tumor and blood sampling before and after treatment.
Blood and tumor sampling will also be performed at disease progression/relapse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsies</intervention_name>
    <description>Tumor biopsies will be performed before and after treatment.</description>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling will be performed before and after treatment.</description>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No prior treatment for cervical cancer.

          2. FIGO Stage IB1 to IVB; all histological subtypes (excluding neuro-endocrine type).

          3. Pelvic MRI available or planned before the start of treatment, , if FIGO ≥ IB2. and
             optional for IB1 stage

          4. Possibility to communicate imaging data by CD-ROM (format DICOM 3.0 or more).

          5. Disease amenable to biopsy (3 tumour samples are mandatory prior to treatment).

          6. Age ≥ 18 years.

          7. ECOG (Eastern Cooperative Oncology Group) 0-2.

          8. Life expectancy &gt; 6 months.

          9. Patient eligible for standard treatment (according to standards of each center).

         10. Patient having health care insurance.

         11. Informed and signed consent by patient.

        (DICOM = Digital Imaging and Communications in Medicine)

        Exclusion Criteria:

          1. Patient enrolled in a clinical trial involving an investigative new agent.

          2. Co morbidity, preventing patient to tolerate the proposed standard treatment.

          3. Past history of invasive cancer over the 5 years preceding entry in the present trial
             (except basal cell carcinoma and carcinoma in situ of the cervix).

          4. Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker,
             metallic implant, non availability, other), ), if FIGO ≥ IB2 .

          5. Patient deprived from ability to decide on her own.

          6. Patient unable to have a regular follow up for geographical, social or psychological
             reasons.

          7. Pregnancy or patient old enough to procreate and not using effective contraceptive
             method.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil - CHI Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier - Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine - ICL</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - RENE GAUDUCHEAU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insitut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine- ICL NANCY</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mhh Hanover - Hanover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <state>Meibergdreef</state>
        <zip>91105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherland Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1006 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teo Health S.A. - Spitalul Sf. Constantin</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal &quot;Gavril Curteanu&quot;</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de radioterapie</name>
      <address>
        <city>Timisoara</city>
        <zip>300041</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for operative oncology, Institute of oncology of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Tumor biopsies</keyword>
  <keyword>Standard treatment</keyword>
  <keyword>Molecular profile</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

